Despite effective interventions such as angiotensin converting enzyme inhibitors and angiotensin-II-type 1(AT1) receptor blockers available to treat diabetic nephropathy[4-5], hitherto, no promising interventions are in the practice that could satisfactorily improve the clinical outcomes of diabetic nephropathy. Current treatment protocol for the management of diabetic nephropathy targets for tight glucose and blood pressure control as hyperglycemia and hypertension are major risk factors for the disease progression of nephropathy[6-7]. In addition, dyslipidemia has been suggested to be strongly associated with an induction and progression of diabetic nephropathy[8-9] While renal lipid accumulation- induced lipotoxicity could develop diabetic nephropathy[10], peroxisome proliferator-activated receptor a (PPARa) agonists could have a place in the treatment of diabetic nephropathy[11]. Experimental and clinical studies suggested that fenofibrate, a fibrate class of hypolipidemic agent, acts as a PPARa agonist, ameliorated diabetic renal damage by preventing renal oxidative stress, inflammation and fibrosis. Our previous studies showed that fenofibrate contributes its beneficial effect to prevent endothelial dysfunction from upregulating level of BH4 and decreasing production of ROS through the mechanism of increasing the level of intracellular GTPCH-I. Fenofibrate may help protect against vascular damage potential by promoting the re-coupling of eNOS with normalizing endothelial disorders[12-13]. Moreover, fenofibrate significantly reduced the pathological changes in glomeruli by improving the glomerular capillary size and reducing the mesangial expansion [14-16].